Julie K. Jadlowsky
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Julie K. Jadlowsky has a total of 297 co-authors. Here are the top co-authors by number of shared publications:
- Carl H. June
University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States
23 shared publications - Joseph A. Fraietta
Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
19 shared publications - Caitlin R. Hopkins
Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
13 shared publications - Ju-Fang Chang
Center for Gene and Cellular Immunotherapy, Washington University School of Medicine, St. Louis, Missouri. 2
13 shared publications - Nathan Singh
Washington University School of Medicine
13 shared publications - Saar Gill
Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
13 shared publications
Latest Publications
- Open Access
- 26 August 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (9) , 3495
Publisher Correction: Decade-long persistence of CD19 CAR T cells in B cell lymphomas
- 26 August 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (9) , 3495
Open AccessPublisher Correction: Decade-long persistence of CD19 CAR T cells in B cell lymphomas
- Open Access
- 10 August 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (9) , 3276-3287
Decade-long persistence of CD19 CAR T cells in B cell lymphomas
Chimeric antigen receptor (CAR) T cell therapy induces durable remissions in lymphoid malignancies, yet the extent and biology of long-term CAR T cell persistence in B cell lymphoma remain unclear. Here we report the persistence and characteristics of 4-1BB-costimulated anti-CD19 CAR T cells (CART19) up to 10 years after infusion in 38 patients with non-Hodgkin lymphoma. Beyond year five, the CAR19 transgene was detectable in five of eight long-term responders (7.0–10.1 years), with three patients maintaining B cell aplasia, which is consistent with sustained functional activity. In one patient with a progression-free survival of 10.1 years, CART19 cells comprised 1.2% of circulating T cells 9.3 years after infusion. Long-term persisting CART19 cells exhibited a predominant double-negative (CD4 − CD8 − ), effector-memory-like phenotype associated with increased aerobic metabolism and T cell activation programs. Longitudinal profiling revealed a progressive transition from CD8 + to double-negative CAR T cells over time. Persisting CART19 shared transcriptional features with long-term CAR T cells described in acute and chronic leukemias. T cell receptor sequencing demonstrated oligoclonal persistence at 9.3 years, with a dominant clone (70% of CART19 cells) already detectable at low frequency (<0.1%) at day 14. Lentiviral integration-site analysis identified a predominant integration within PACS1 without evidence of known drivers of CAR T cell expansion. These findings demonstrate that CART19 cells can persist for more than 10 years in lymphoma and identify phenotypic, transcriptional and clonal features associated with exceptionally long-term persistence. ClinicalTrials.gov registration: NCT02030834
- 10 August 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (9) , 3276-3287
Open AccessDecade-long persistence of CD19 CAR T cells in B cell lymphomas
Chimeric antigen receptor (CAR) T cell therapy induces durable remissions in lymphoid malignancies, yet the extent and biology of long-term CAR T cell persistence in B cell lymphoma remain unclear. Here we report the persistence and characteristics of 4-1BB-costimulated anti-CD19 CAR T cells (CART19) up to 10 years after infusion in 38 patients with non-Hodgkin lymphoma. Beyond year five, the CAR19 transgene was detectable in five of eight long-term responders (7.0–10.1 years), with three patients maintaining B cell aplasia, which is consistent with sustained functional activity. In one patient with a progression-free survival of 10.1 years, CART19 cells comprised 1.2% of circulating T cells 9.3 years after infusion. Long-term persisting CART19 cells exhibited a predominant double-negative (CD4 − CD8 − ), effector-memory-like phenotype associated with increased aerobic metabolism and T cell activation programs. Longitudinal profiling revealed a progressive transition from CD8 + to double-negative CAR T cells over time. Persisting CART19 shared transcriptional features with long-term CAR T cells described in acute and chronic leukemias. T cell receptor sequencing demonstrated oligoclonal persistence at 9.3 years, with a dominant clone (70% of CART19 cells) already detectable at low frequency (<0.1%) at day 14. Lentiviral integration-site analysis identified a predominant integration within PACS1 without evidence of known drivers of CAR T cell expansion. These findings demonstrate that CART19 cells can persist for more than 10 years in lymphoma and identify phenotypic, transcriptional and clonal features associated with exceptionally long-term persistence. ClinicalTrials.gov registration: NCT02030834
- Open Access
- 3 July 2026
- Published by Springer Nature in Research Square
HIV-specific and resistant CAR T cells promote control of HIV replication in people with HIV
We conducted a first-in-human evaluation of HIV-specific, HIV-resistant chimeric antigen receptor (CAR) T cells (CARTs) to determine their capacity to modulate viral rebound dynamics following analytic treatment interruption (ATI). Among ten treated individuals who received engineered T cells, one individual did not rebound during the ATI and had a remarkable expansion of their CARTs 43 days after the start of the ATI, suggesting that the CARTs recognized rebounding HIV and prevented its spread. Post-rebound virologic control was observed in 1 participant for 90 weeks and another 5 participants had remarkable reductions in their viral load after viral peak was reached, maintaining viral loads below their set point. CART infusion was associated with broad reinvigoration of endogenous HIV-specific CD8 T cell responses, and immune escape to one of these responses was documented. Together, these findings show that HIV-specific CARTs can be an integral component in HIV Cure strategies.
- 3 July 2026
- Published by Springer Nature in Research Square
Open AccessHIV-specific and resistant CAR T cells promote control of HIV replication in people with HIV
We conducted a first-in-human evaluation of HIV-specific, HIV-resistant chimeric antigen receptor (CAR) T cells (CARTs) to determine their capacity to modulate viral rebound dynamics following analytic treatment interruption (ATI). Among ten treated individuals who received engineered T cells, one individual did not rebound during the ATI and had a remarkable expansion of their CARTs 43 days after the start of the ATI, suggesting that the CARTs recognized rebounding HIV and prevented its spread. Post-rebound virologic control was observed in 1 participant for 90 weeks and another 5 participants had remarkable reductions in their viral load after viral peak was reached, maintaining viral loads below their set point. CART infusion was associated with broad reinvigoration of endogenous HIV-specific CD8 T cell responses, and immune escape to one of these responses was documented. Together, these findings show that HIV-specific CARTs can be an integral component in HIV Cure strategies.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Identification of Core Techniques That Enhance Genome Editing of Human T Cells Expressing Synthetic Antigen Receptors
A, Expansion of T cells in which stimulation cultures did or did not contain IL7/IL15. B, CD4 and CD8 composition of and C, memory composition of T cell products at the conclusion of manufacturing when stimulation cultures did or did not include IL7/IL15.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Identification of Core Techniques That Enhance Genome Editing of Human T Cells Expressing Synthetic Antigen Receptors
A, Expansion of T cells in which stimulation cultures did or did not contain IL7/IL15. B, CD4 and CD8 composition of and C, memory composition of T cell products at the conclusion of manufacturing when stimulation cultures did or did not include IL7/IL15.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Identification of Core Techniques That Enhance Genome Editing of Human T Cells Expressing Synthetic Antigen Receptors
A, Representative ow cytometry plots of transduction efficiency of various synthetic receptors in control (unedited) and TRAC+TRBCKO T cells when editing is performed pre-stimulation. B, Stability of CRISPR editing over-time when performing post-stimulation editing.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Identification of Core Techniques That Enhance Genome Editing of Human T Cells Expressing Synthetic Antigen Receptors
A, Representative ow cytometry plots of transduction efficiency of various synthetic receptors in control (unedited) and TRAC+TRBCKO T cells when editing is performed pre-stimulation. B, Stability of CRISPR editing over-time when performing post-stimulation editing.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Identification of Core Techniques That Enhance Genome Editing of Human T Cells Expressing Synthetic Antigen Receptors
Supplementary Tables S1 and S2
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Identification of Core Techniques That Enhance Genome Editing of Human T Cells Expressing Synthetic Antigen Receptors
Supplementary Tables S1 and S2
- 9 March 2026
- Published by Springer Nature in Nature Biomedical Engineering
- Vol. 10 (4) , 803-814
Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer
Chimeric antigen receptor (CAR) T-cell therapy holds great promise for patients with cancer, and the identification of predictive biomarkers is crucial in finding new ways to guide therapy. Major challenges to the application of informatics and machine learning in CAR T-cell therapy include limited sample sizes and non-uniformity in data generation across cancer indications and trials. Here we took a global, pan-haematologic cancer approach, analysing 256 patients across 5 cancer types and 13 clinical trials. We generated data using a framework that included pre-infusion clinical features, over 2 million apheresis T cells analysed by flow cytometry using 17 unique markers, ex vivo T-cell expansion during CAR T-cell manufacture, more than 90,000 measurements of 30 serum markers and serial tracking of circulating CAR T cells using qPCR. From this data resource, we demonstrate the potential of pan-cancer predictive biomarkers that capture generalizable characteristics of treatment response and non-response in CAR T-cell therapy.
- 9 March 2026
- Published by Springer Nature in Nature Biomedical Engineering
- Vol. 10 (4) , 803-814
Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer
Chimeric antigen receptor (CAR) T-cell therapy holds great promise for patients with cancer, and the identification of predictive biomarkers is crucial in finding new ways to guide therapy. Major challenges to the application of informatics and machine learning in CAR T-cell therapy include limited sample sizes and non-uniformity in data generation across cancer indications and trials. Here we took a global, pan-haematologic cancer approach, analysing 256 patients across 5 cancer types and 13 clinical trials. We generated data using a framework that included pre-infusion clinical features, over 2 million apheresis T cells analysed by flow cytometry using 17 unique markers, ex vivo T-cell expansion during CAR T-cell manufacture, more than 90,000 measurements of 30 serum markers and serial tracking of circulating CAR T cells using qPCR. From this data resource, we demonstrate the potential of pan-cancer predictive biomarkers that capture generalizable characteristics of treatment response and non-response in CAR T-cell therapy.
- Open Access
- 4 February 2026
- Published by Springer Nature in Research Square
Cell-derived Nanoparticles Provide a Robust Platform to Manufacture Therapeutic T cells.
Some patients cannot receive T cell therapies because their cells are unable to be manufactured. To address this limitation, we developed K562-based artificial antigen-presenting cells (aAPCs) expressing an OKT3-derived scFv for TCR stimulation, CD86 and 4-1BBL for costimulation, and membrane-bound IL-7 and IL-15Rα/IL-15 for cytokine support. From these aAPCs, we generated cell-derived nanoparticles (CDNPs) that accelerated T cell entry into the cell cycle compared with CD3/28-coated beads, enabling efficient concurrent activation and lentiviral transduction. CDNPs robustly expanded T cells from patients whose products could not be manufactured using standard approaches, and these CDNP-derived CAR T cells controlled tumors in humanized mouse models. In a phase I trial of patients with CD19⁺ malignancies (NCT04684563), cGMP-compatible CDNPs enabled streamlined 3-day manufacturing of IL-18–expressing CD19 CAR T cells, yielding higher cell recovery and durable clinical responses without unexpected toxicities, supporting CDNPs as a platform for commercial CAR T cell production.
- 4 February 2026
- Published by Springer Nature in Research Square
Open AccessCell-derived Nanoparticles Provide a Robust Platform to Manufacture Therapeutic T cells.
Some patients cannot receive T cell therapies because their cells are unable to be manufactured. To address this limitation, we developed K562-based artificial antigen-presenting cells (aAPCs) expressing an OKT3-derived scFv for TCR stimulation, CD86 and 4-1BBL for costimulation, and membrane-bound IL-7 and IL-15Rα/IL-15 for cytokine support. From these aAPCs, we generated cell-derived nanoparticles (CDNPs) that accelerated T cell entry into the cell cycle compared with CD3/28-coated beads, enabling efficient concurrent activation and lentiviral transduction. CDNPs robustly expanded T cells from patients whose products could not be manufactured using standard approaches, and these CDNP-derived CAR T cells controlled tumors in humanized mouse models. In a phase I trial of patients with CD19⁺ malignancies (NCT04684563), cGMP-compatible CDNPs enabled streamlined 3-day manufacturing of IL-18–expressing CD19 CAR T cells, yielding higher cell recovery and durable clinical responses without unexpected toxicities, supporting CDNPs as a platform for commercial CAR T cell production.
- 21 October 2025
- Published by Springer Nature in Nature Biomedical Engineering
- Vol. 10 (7) , 1-15
CCR5-targeted allogeneic gamma–delta CD19 chimeric antigen receptor T cells for HIV-associated B cell-malignancy immunotherapy
Immune-based cell therapy offers a promising approach to cancer treatment. While autologous chimeric antigen receptor (CAR) T cells have shown success, production is time-consuming, costly and patient specific. Gamma–delta (γδ) T cells are promising for ‘off-the-shelf’ CAR T cell therapy. However, clinical translation of γδ CAR T cells is hampered by low frequency, resistance to genetic manipulation and advanced differentiation after expansion, limiting therapeutic feasibility. Here we demonstrate a method for in vitro activation and expansion of peripheral blood γδ T cells, facilitating high rates of gene editing and efficient CAR integration. Using artificial antigen-presenting cells, we produce minimally differentiated, highly functional γδ CAR T cells. By targeting a US Food and Drug Administration-approved CD19 CAR to the CCR5 locus, we generate CCR5-deficient γδ CD19 CAR T cells (γδ CCR5KI-CAR19), which demonstrated resistance to HIV-mediated depletion and robust antitumour responses against B cell lymphoma and leukaemia. γδ CCR5KI-CAR19 T cells enable the immunotherapy of HIV-associated B cell malignancies. These studies provide preclinical evidence supporting large-scale development of potent allogeneic γδ CAR T cells for diverse immunotherapies.
- 21 October 2025
- Published by Springer Nature in Nature Biomedical Engineering
- Vol. 10 (7) , 1-15
CCR5-targeted allogeneic gamma–delta CD19 chimeric antigen receptor T cells for HIV-associated B cell-malignancy immunotherapy
Immune-based cell therapy offers a promising approach to cancer treatment. While autologous chimeric antigen receptor (CAR) T cells have shown success, production is time-consuming, costly and patient specific. Gamma–delta (γδ) T cells are promising for ‘off-the-shelf’ CAR T cell therapy. However, clinical translation of γδ CAR T cells is hampered by low frequency, resistance to genetic manipulation and advanced differentiation after expansion, limiting therapeutic feasibility. Here we demonstrate a method for in vitro activation and expansion of peripheral blood γδ T cells, facilitating high rates of gene editing and efficient CAR integration. Using artificial antigen-presenting cells, we produce minimally differentiated, highly functional γδ CAR T cells. By targeting a US Food and Drug Administration-approved CD19 CAR to the CCR5 locus, we generate CCR5-deficient γδ CD19 CAR T cells (γδ CCR5KI-CAR19), which demonstrated resistance to HIV-mediated depletion and robust antitumour responses against B cell lymphoma and leukaemia. γδ CCR5KI-CAR19 T cells enable the immunotherapy of HIV-associated B cell malignancies. These studies provide preclinical evidence supporting large-scale development of potent allogeneic γδ CAR T cells for diverse immunotherapies.
- Open Access
- 11 June 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (9) , 3205
Author Correction: Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial
- 11 June 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (9) , 3205
Open AccessAuthor Correction: Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial